| Popis: |
From the 1st June 1975 to 1st March 1990 a hundred patients with locally advanced carcinoma of the breast were treated with Neo-Adjuvant chemotherapy. The mean age of our group was 50.7 years (median 49 years, range 23–71 years). 60 % of the patients were non or pre-menopaused while 40 % were menopaused. 87 % of the tumors could be classified T3 or T4 while only 13 % were T2. The clinical nodal status was N1 for 70 % of the patients, N2 for 6 % and N3 for 7 %. 89 % were classified stage IIIA or HIB. All patients had a negative metastatic staging. Clinical inflammation of the tumor was evaluated and classified PEV0 in 16 patients, PEV1 in 51, PEV2 in 26 and PEV3 in 7. Histopathology was undifferentiated carcinoma in 77 % of the cases. Histologic grading was SBRI for 8 patients, SBRII for 42 and SBRIII for 13. The oestrogen and progesterone receptors were totally negative in 28 patients, both present in 26 patients and only one positive receptor could be detected in 22 patients. 44 patients (1975–1981) received the AVM1 protocol every 4 weeks: Adriamycin (50 mg/m2, IV, J1), Vincristine (1 mg/m2 IV, J2), Methotrexate (7,5 mg/m2 SC, J3-J4-J5). 34 patients (1982–1987) received the weekly AVM2 protocol: Adriamycin (13 mg/m2, IV, J1), Vindesine (2 mg/m2 IV, J1), Methotrexate (6 mg/m2 SC, J2). 22 patients (1987–1990) received the NVM protocol: Mitoxantrone (13 mg/m2, IV, J1), Vindesine (2 mg/m2 IV, J2), Methotrexate (6 mg/m2 SC, J3-J4-J5). |
